ABSTRACT
Objective To explore the correlation of the pan-immune-inflammation value (PIV) and the prognosis of patients with resectable colorectal cancer (CRC) and establish a predictive model. Methods A total of 753 patients who underwent primary lesion resection and were pathologically diagnosed with CRC were enrolled. They were randomly divided into training (n=527) and test (n=226) cohorts. The best cutoff value of PIV was determined by the time-dependent receiver operator characteristics curve, and patients were divided into high- and low-level groups to analyze the relationship between the high- and low-level groups of PIV and the clinicopathological characteristics and survival of patients. Chi-square test, Kaplan-Meier survival analysis, and Cox regression analysis were used to evaluate the prognosis. The accuracy of the model was evaluated by C index and Brier score. Results In the univariate model of overall survival (OS), high (> 231) baseline PIV (HR=1.627; 95%CI: 1.155-2.292, P=0.005) suggested that PIV level might be an independent prognostic factor for OS. The nomogram plotted according to PIV had a C index of 0.823. Its calibration curve showed good agreement between predicted and observed outcomes for one- and three-year OS probabilities, with Brier score of 0.035 and 0.068 for OS, respectively. Conclusion PIV can be used as a prognostic marker in patients with resectable CRC, and a novel prognostic model to guide clinical decision-making in CRC is successfully established.
ABSTRACT
In recent years, immunotherapy has achieved great progress in the treatment of malignant tumors and has enriched the treatment mode of many types of malignant tumors. Colorectal cancer is a common tumor worldwide. Immune checkpoint inhibitor therapy for patients with metastatic colorectal cancer (mCRC) featuring DNA mismatch repair deficiency/high microsatellite instability has significant clinical benefits, but approximately 95% of patients with mCRC are DNA mismatch repair proficient/microsatellite stable (MSS). These patients have poor response to immunotherapy. Therefore, strategies to improve the efficacy of immunotherapy in patients with this type of tumor have attracted considerable attention. This article reviews the research progress on combined immunotherapy for MSS mCRC.
ABSTRACT
In recent years, with the development of comprehensive tumor therapy, hyperthermia has become one of the important means of cancer treatment. A large number of studies have shown that the removal of tumor cells depends on exogenous treatment methods and the body's own anti-tumor immune status. Hyperthermia cannot only directly kill tumor cells but also activate the body's immunity to exhibit an anti-tumor effect. In recent years, with the deepening of tumor research, hyperthermia has been able to create a type I tumor microenvironment with PD-L1 overexpression and enrichment of tumor-infiltrating lymphocytes, complementing the enhancement of immune checkpoint inhibitors. Hyperthermia combined with immunotherapy may offer a new perspective in cancer treatment. The mechanism of tumor hyperthermia and anti-tumor immunity and its clinical application have aroused great interest and become a new research field. This article reviews the relationship between tumor hyperthermia and anti-tumor immunity.
ABSTRACT
Recently, the incidence of colorectal cancer in China has increased yearly, and it has become one of the most common ma-lignant tumors of the digestive tract. With in-depth molecular biology and metagenomics studies, it has been found that changes in the intestinal microflora and its metabolic patterns can be achieved by destroying normal tissue cell DNA, activating oncogenic signal-ing pathways and producing tumor-promoting metabolites and inhibitory antibodies. Multiple factors such as the tumor immune re-sponse affect the occurrence and development of colorectal cancer. Therefore, attempts have been made to treat and prevent tumors using microecological agents. Through research, it is found that microecological preparations represented by probiotics and excreta transplantation technology can regulate intestinal microflora, induce apoptosis and cell cycle arrest of colorectal cancer cells, secrete anti-tumor cytokines, and regulate the immune system to resist tumors. Microecological preparations have brought hope to patients with colorectal cancer, but the specific mechanism of action of intestinal microflora in colorectal cancer is still unclear, and further large-scale studies are needed. This article reviews the research progress of intestinal microflora and colorectal cancer in order to ex-plore a new method for the diagnosis and treatment of colorectal cancer.
ABSTRACT
Objective To observe the effect of 5-Aza-CdR on the proliferation and apoptosis of colon cancer cells and the expression of PTEN and to explore its mechanism Methods Different concentrations of 5-Aza-CdR (1, 2, 5,10 μmol/L) were used in vitro on HT-29 cells and the proliferation was detected by MTT assay and the apoptosis was detected by flow cytometry. PTEN mRNA and protein expression changes were observed by real-time PCR and Western blot. Results Different concentrations of 5-Aza-CdR (2, 5,10 μmol/L) could inhibit the proliferation of HT-29 cells with dose and time dependent manner. With the increase of time and dose, the inhibition rate of HT-29 cells increased gradually and the difference was significant. (P < 0.05). After 5-Aza-CdR treated for 48h , the apoptosis rates of HT-29 cells in control and 1 , 2 , 5 , 10 μmol/L group were 2.443 ± 0.210 1, 3.900 ± 0.665 1, 14.07 ± 1.206, 24.70 ± 2.506, and 30.60 ± 2.390 respectively, which were significantly increased and the apoptosis rate increased with the increase of dose , which was statistically significant (P < 0.05). The PTEN mRNA and protein expression of HT-29 cells were gradually increased when treated by different concentrations of 5-Aza-CdR. Conclusion 5-Aza-CdR might induce the expression of PTEN by demethylation and then inhibit the proliferation and induce apoptosis of HT-29 cells.